

EZETIMIBE SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta Government sponsored drug programs.

processed.	by Alberta Government sponsored drug programs.					
PATIENT INFORMATION			COVERAGE TYPE:			
PATIENT LAST NAME	FIR	ST NAME			INITIAL	☐ Alberta Blue Cross☐ Alberta Human Services
DATE OF BIRTH: Year / Month / Day	ALE	BERTA PERSONAL HEA	LTH NUMBER	NUMBER		Other
STREET ADDRESS C		CITY	PROV	P	OSTAL CODE	IDENTIFICATION/CLIENT/COVERAGE No:
PRESCRIBER INFORMATION						
PRESCRIBER LAST NAME FIRST NAME INITIA			PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION			
STREET ADDRESS			☐ CPSA ☐ ACO REGISTRATION NO. ☐ CARNA ☐ ADA+C ☐ ACP ☐ Other			
			PHONE: FAX:			
CITY, PROVINCE						
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED			
Criteria for Coverage of EZETIMIBE						
*High cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular disease and/or cerebrovascular disease, or diabetes, or *greater than or equal to 20% risk as defined by the Framingham Risk Assessment Tool, OR *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular disease and/or cerebrovascular disease, or *diabetes, or *greater than or equal to 20% risk as defined by the Framingham Risk Assessment Tool, OR *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular disease and/or cerebrovascular disease, or *diabetes, or *familial hypercholesterolemia, or *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular disease and/or cerebrovascular disease, or *diabetes, or *familial hypercholesterolemia, or *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined as possessing one of the following: *high cardiovascular risk is defined by the Framingham Risk Assessment Tool, OR *high cardiovascular risk is defined by the Framingham Risk Assessment Tool, OR *high cardiovascular risk is defined by the Framingham						
NEW Please provide the following information for all NEW requests: A. Diagnosis: hypercholesterolemia other, please specify						
B. Information regarding previous STATIN use:						
Statin(s) HAS been utilized. Please specify which statin has been utilized (including dose and duration):						
Nature of response to STATIN: Intolerance Failure to achieve target LDL Other						
Statin(s) has NOT been utilized. Contraindication? Yes No Please elaborate:						
C. Presence of CARDIOVASCULAR risk factors (CHECK ALL THAT APPLY):						
In order to comply with the above criteria check at least three of the following:						
family history of premature cardiovascular disease smoking hypertension obesity glucose intolerance renal disease AND/OR In order to comply with the above criteria check at least one of the following: pre-existing cardiovascular disease and/or cerebrovascular disease diabetes familial hypercholesterolemia greater than or equal to 20% risk as defined by the Framingham Risk Assessment Tool						
D. Additional information relating to request:						
RENEWAL This product is eligible for auto-renewal. A Special Authorization renewal request is required only if the Special Authorization approval has lapsed (i.e. the patient has not made a claim for the drug product during the Approval Period). Please indicate response to therapy:						
PRESCRIBER'S SIGNATURE	DATE		Please forward this request to: • Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 • FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll-free all other areas			
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED. PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.						

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street, Edmonton AB T5J 3C5.